Mar 15, 2023

Multi-state study reports COVID-19 mRNA vaccines protective during omicron BA.4/BA.5 predominance

Posted by in category: biotech/medical

A multi-state study from the U.S. Center for Disease Control and Prevention’s (CDC) VISION Network has found that first-generation COVID-19 mRNA vaccines were associated with protection against COVID-19 during periods of omicron BA.4/BA.5 predominance.

The new analysis found that mRNA vaccines were protective against COVID-19-associated hospitalization and ICU admission or in-hospital death and noted less during BA.4/BA.5 predominance compared to earlier omicron variants.

During BA.4/BA.5 predominance, estimated 3-dose vaccine effectiveness against hospitalization was 68 percent between 7-and 119-days post-vaccination. Vaccine effectiveness against hospitalization decreased to 36 percent by 120 days or more post-vaccination.

Comments are closed.